ASCO International Affairs Committee Leaders Discuss Global Oncology Priorities

“The biggest concern [in cancer care globally today] is equity…,” said Monica Malik, MD, DNB, FASCO, Immediate Past Chair of the ASCO International Affairs Committee, in an interview with The ASCO Post.

The comment frames a widening crisis: by 2050, cancer deaths are projected to surge 155% in low-income countries versus 56% in high-income nations, a mortality gap driven not by a lack of medical knowledge but by the failure to implement it.

At the 2026 ASCO Annual Meeting, then-President Eric J. Small, MD, FASCO, called on the oncology community to translate knowledge “across languages, cultures, geographies, resource availability, and practice sites, so that all patients can benefit.”

The drivers of that gap look radically different depending on where you stand. In India, the sheer volume of patients strains a system that already houses world-class centers — if you can reach and afford them in the urban cores where they cluster.

“Those disparities should not, however, be understood simply as a lack of sophisticated oncology care,” Dr. Malik told The ASCO Post. She emphasized that low-resource pockets exist inside wealthy countries, too.

In Central and Eastern Europe, the bottleneck is systemic. Piotr Rutkowski, MD, PhD, FASCO, the Committee’s current Chair, pointed to limited financing, gaps in screening uptake, delayed diagnoses, prolonged wait times, bureaucratic barriers to newer therapies, and an overburdened workforce. “Effective access also depends on having an organized health system,” Dr. Rutkowski said, noting access varies considerably between countries and between rural areas and major cities.

Argentina presents a third paradigm: expertise and infrastructure exist, but the delivery vehicle is broken. Matías Chacón, MD, Chair-Elect of the Committee, described a “deficit of implementation” — the distance between what evidence indicates can be achieved and what health systems actually deliver.

“There is not a difference in terms of knowledge,” Dr. Chacón told The ASCO Post. Cancer care there runs through three poorly coordinated subsystems: social security funds, private prepaid insurance, and the public sector. “Structural fragmentation of the health system is the main problem,” said Dr. Chacón.

The Pivot From Charity to Co-Development

ASCO’s response has shifted from exporting Western protocols to facilitating a two-way exchange. Dr. Malik pointed to the Leadership Development Program and emphasized its reach into the Asia-Pacific and Latin American regions.

She highlighted research capacity as a further key aspect of ASCO’s international work, singling out the International Innovation Grant, which backs pragmatic projects in low- and middle-income countries that “may not always be cutting-edge research or drug development” but can have substantial implications for cancer care in those settings.

Dr. Rutkowski similarly flagged expanding clinical trial equity in these countries as a long-term goal, citing clinical cancer research workshops held in his region as a way ASCO is supporting that effort.

“It has launched many careers and created leaders…,” Dr. Malik said. Dr. Rutkowski added that many current oncology leaders outside the United States are former IDEA fellows, “which means it really impacts people’s lives and careers in oncology.”

The Leadership Development Program extends that reach into Asia-Pacific and Latin America. The International Innovation Grant funds pragmatic projects — not necessarily cutting-edge drug development — that carry substantial implications for local care. Dr. Rutkowski cited clinical cancer research workshops in his region as a step toward expanding clinical trial equity, a long-term goal.

Regional Councils as the Operating System

Four regional councils — Asia-Pacific, Latin America, Sub-Saharan Africa, and Central and Eastern Europe — now function as the mechanism ensuring ASCO’s international efforts reflect local priorities. Dr. Chacón called them “one of the most important things that [the organization] provides to the world right now.”

Dr. Rutkowski wants the councils to cross-pollinate. He pointed to the molecular tumor board program associated with the Central and Eastern Europe Council as a successful initiative ready for broader adoption. Other vehicles — the Quality Oncology Practice Initiative (QOPI) Certification Program, global courses, and ASCO Breakthrough meetings — disperse knowledge across more than 170 countries attending ASCO meetings, Dr. Rutkowski noted.

Innovation Flowing South to North

The most striking insight from the discussion is the reversal of the traditional innovation vector. “If we prove that less is enough or not inferior,” Dr. Malik said, “the findings could improve sustainability internationally.” She argued that countries like India “can and are taking the lead in driving these kinds of innovative practices” to address rising costs in high-income systems.

Digital infrastructure offers another export. In Estonia, “almost everything is digitalized,” Dr. Rutkowski said. In Latvia, a centralized system allows a physician to access a patient’s examinations and imaging from across the country using a single code — capabilities that proved vital during the COVID-19 pandemic and remain in use.

Argentina contributed a public health model: a cervical cancer screening program deploying community health workers to offer HPV DNA self-collection during routine home visits. Dr. Chacón said the approach could be adapted for other parts of the world where clinic access remains a barrier.

The through-line is clear. Inequity is not an absence of expertise. It is a failure of connection — between patients and existing care, between evidence and practice, and between regions solving the same problems in isolation. The ASCO Post reported that the Committee’s next phase hinges on whether those connections can be hardened into durable systems.